MedImmune

Executive Summary

Planned acquisition of Melville Biologics is terminated by Gaithersburg, Md. firm Dec. 20. MedImmune had signed a letter of intent to acquire the division of the New York Blood Center in September ("The Pink Sheet" Sept. 20, 1993, T&G-13). The agreement called for MedImmune to issue $40 mil. in stock for the acquisition; however, in the wake of an advisory committee rejection of MedImmune's RespiGam and a subsequent plunge in MedImmune stock prices, MedImmune does "not believe the Melville acquisition is in the best interest of our shareholders at this time"